Evelyn Reyes
Primary Care · Las Vegas, NVNPI 1093271132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $514 and has fallen 56.3% since, to $224 in 2025.
Across 70 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$155
- AstraZeneca$154
- Takeda Pharmaceuticals U.S.A., Inc.$143
- Novo Nordisk$137
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$102
- GSK$99
- plus $828 from 25 others
What the payments were for
- Food & beverage$1,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 4 | $155 |
| AstraZeneca | 4 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $143 |
| Novo Nordisk | 2 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $102 |
| GSK | 5 | $99 |
| Pfizer | 4 | $89 |
| Lucid Diagnostics Inc. | 5 | $84 |
| Amgen | 3 | $58 |
| Intra-sana Laboratories | 3 | $54 |
| Grifols USA, LLC | 2 | $49 |
| Harmony Biosciences LLC | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Abbott | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Novartis | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Inogen, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $21 |
| Mannkind Corporation | 1 | $20 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Electromed, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Optinose US, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,619 in reported general payments places this provider in the 80th percentile of 81 primary care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 59 | $73,914 |
| TrulicityDulaglutide | 34 | $44,265 |
| JardianceEmpagliflozin | 17 | $20,654 |
| LinzessLinaclotide | 13 | $12,743 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,352 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $988 |
| Atorvastatin Calcium | 129 | $802 |
| Gabapentin | 43 | $700 |
| Omeprazole | 57 | $657 |
| Doxycycline Monohydrate | 19 | $557 |
| Losartan Potassium | 81 | $484 |
| Amlodipine Besylate | 77 | $456 |
| Metformin Hcl | 84 | $414 |
| Levothyroxine Sodium | 49 | $376 |
| Mupirocin | 33 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $29 | $118,17993 claims |
| Boehringer IngelheimJardiance | $15 | $20,65417 claims |
| AbbVieLinzess | $14 | $12,74313 claims |
| AstraZenecaBreztri Aerosphere | $154 | $12,35220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 primary care providers in Nevada.
Other primary care in Las Vegas
- Jennifer CribbLas Vegas$7K
- Ruel MarianoLas Vegas$4K
- George Gabriel ToldnessLas Vegas$4K
- Jona SteadLas Vegas$3K
- Mario LuglioLas Vegas$3K
- Jocybel ItorralbaLas Vegas$3K
- Jerifaye FloresLas Vegas$2K
- Sneha ThomasLas Vegas$2K
- Yoslady MoralesLas Vegas$2K
- Christine EspenillaLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.